Allen Chao was named CEO of Zephyr AI, a company focused on utilizing artificial intelligence to accelerate drug development.
Qure.ai has appointed Javier J. Zulueta, previously professor of medicine at the Icahn School of Medicine at Mount Sinai in New York and pulmonary division chief at Mount Sinai Morningside Hospital, as chief medical officer for pulmonology.
Libtayo (cemiplimab) plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone, according to late-breaking data from exploratory analyses at World Conference on Lung Cancer.
Rezatapopt monotherapy generated a 33% overall response rate in 97 patients with solid tumors spanning across eight different cancers (ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma) and a median duration of response of 6.2 months, according to PYNNACLE phase II clinical trial interim data. These were patients whose tumors were TP53 Y220C mutated and KRAS wild-type.
Twenty-seven species of bacteria and fungi, among the hundreds that live in people’s mouths, have been collectively tied to a 3.5 times greater risk of developing pancreatic cancer, according to a study led by NYU Langone Health and its Perlmutter Cancer Center.
A team of scientists at Sanford Burnham Prebys and the University of Zurich in Switzerland identified a specific phosphoinositide kinase called PI5P4Kα as critical to supporting the unique demands of pancreatic ductal adenocarcinoma cells.
Glioblastoma cells that “cluster” together with other cells of the same type are less deadly than those that disperse from these clusters, according to findings from researchers at the Sylvester Comprehensive Cancer Center part of the University of Miami Miller School of Medicine.
The ZUMA-24 phase II clinical trial demonstrates the safety and feasibility of administering Yescarta (axi-cel) in the outpatient setting when treating relapsed or refractory large B-cell lymphoma.
Researchers from UVA Cancer Center, the University of Virginia School of Medicine, and Inova Peterson Life with Cancer detail the many ways artificial intelligence could help ensure patients receive the support they need.
A novel method could test for prostate cancer using biomarkers present in urine, according to the findings from a diagnostic case control study.
